Integrated · Global · Forward
Genegobio Inc. bridges breakthrough science and global markets — synchronizing strategic capital, pharmaceutical expertise, and critical healthcare infrastructure to accelerate the next generation of medical breakthroughs.
Who We Are
At Genegobio, we don’t just provide funding — we orchestrate ecosystems. We empower biotech pioneers and medtech innovators with the capital, intelligence, and market access essential for sustainable success.
We identify and nurture high-growth opportunities in ADCs, biosimilars, cell & gene therapy, and precision oncology. Delivering targeted capital and expert advisory to accelerate innovative molecules from pipeline to market.
Specialized in next-generation modalities including Antibody-Drug Conjugates (ADCs), biosimilars, and targeted biologics. We provide end-to-end CMC support, IND/NDA regulatory strategy, and seamless cross-border technology transfer.
Securing the global supply of high-purity rare gases (neon, krypton, xenon), rare earth metals, copper, and aluminum — critical inputs for semiconductor fabrication, EV battery systems, and advanced automotive manufacturing.
Founded 2012 · Irvine, California, USA
“We bridge the gap between scientific innovation and global market reality.”
What We Do
A fully integrated platform delivering capital, intelligence, and global market access to healthcare innovators worldwide.
Targeted capital allocation and expert advisory for ADC platforms, biosimilar pipelines, precision oncology, and next-generation biologic ventures. We transform promising molecules into commercially viable market leaders.
Sophisticated licensing frameworks and monetization strategies that convert intellectual property into sustainable global revenue streams for pharma and medtech clients.
End-to-end market entry and technology transfer across the US, Latin America, China, EAEU, and MENA — with localized compliance, manufacturing partnerships, and distribution.
End-to-end procurement and supply chain management for mission-critical materials — high-purity rare gases (neon, krypton, xenon) for semiconductor lithography, rare earth metals, and industrial-grade copper and aluminum for EV battery systems and automotive components.
Full-spectrum CRO capabilities spanning Antibody-Drug Conjugates (ADCs), biosimilar development, cell & gene therapy, and targeted biologics. We support lead optimization, preclinical studies, CMC development, analytical method validation, and regulatory filing strategy from IND through BLA/NDA.
Expert deal negotiation, royalty optimization, post-deal compliance, and lifecycle management for pharmaceutical and medical device licensing agreements across global markets.
Why It Matters
In pharmaceutical and medical device deals, the difference between a good agreement and a great one — or a failed one — comes down to expert licensing guidance at every stage of the deal lifecycle.
🔈 AMBIENT MUSIC PLAYS DURING EXPLAINER — PRESS PLAY TO START | SPEAKER ICON TO MUTE
Licensing advisors protect your IP value, negotiate royalty structures, milestone payments, and exclusivity terms that novice negotiators leave on the table.
Pharma and medtech licensing must align with FDA, EMA, and international regulatory frameworks. An advisor ensures agreements survive regulatory scrutiny globally.
Most licensing failures happen after signing. Advisors monitor milestones, audit royalty payments, manage sub-licensing rights, and enforce compliance over the deal lifecycle.
Cross-border pharma/medtech deals require jurisdiction-specific expertise. Advisors navigate territorial rights, local compliance, and market-specific commercialization strategies.
Global Footprint
With robust infrastructure spanning five major global regions, we specialize in navigating the most complex regulatory and market environments in life sciences.
Get In Touch
Whether you’re a biotech innovator seeking strategic capital, a pharmaceutical firm exploring licensing advisory, or an investor seeking life sciences exposure — we’d like to hear from you.